169 related articles for article (PubMed ID: 10511057)
1. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
3. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
4. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
5. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
6. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.
Kinirons MT; O'Shea D; Downing TE; Fitzwilliam AT; Joellenbeck L; Groopman JD; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1993 Dec; 54(6):621-9. PubMed ID: 8275617
[TBL] [Abstract][Full Text] [Related]
7. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
8. Erythromycin breath test.
Watkins PB
Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
[No Abstract] [Full Text] [Related]
9. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe.
Tateishi T; Watanabe M; Nakura H; Asoh M; Shirai H; Mizorogi Y; Kobayashi S; Thummel KE; Wilkinson GR
Clin Pharmacol Ther; 2001 May; 69(5):333-9. PubMed ID: 11372001
[TBL] [Abstract][Full Text] [Related]
10. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.
McCrea J; Prueksaritanont T; Gertz BJ; Carides A; Gillen L; Antonello S; Brucker MJ; Miller-Stein C; Osborne B; Waldman S
J Clin Pharmacol; 1999 Dec; 39(12):1212-20. PubMed ID: 10586386
[TBL] [Abstract][Full Text] [Related]
11. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
12. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
[TBL] [Abstract][Full Text] [Related]
13. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
14. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.
Hunt CM; Westerkam WR; Stave GM; Wilson JA
Mech Ageing Dev; 1992 Jun; 64(1-2):189-99. PubMed ID: 1630156
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
Prueksaritanont T; Vega JM; Rogers JD; Gagliano K; Greenberg HE; Gillen L; Brucker MJ; McLoughlin D; Wong PH; Waldman SA
J Clin Pharmacol; 2000 Nov; 40(11):1274-9. PubMed ID: 11075313
[TBL] [Abstract][Full Text] [Related]
16. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
17. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
[TBL] [Abstract][Full Text] [Related]
18. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.
Wandel C; Böcker RH; Böhrer H; deVries JX; Hofmann W; Walter K; Kleingeist B; Neff S; Ding R; Walter-Sack I; Martin E
Drug Metab Dispos; 1998 Feb; 26(2):110-4. PubMed ID: 9456296
[TBL] [Abstract][Full Text] [Related]
19. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.
Kashuba AD; Bertino JS; Rocci ML; Kulawy RW; Beck DJ; Nafziger AN
Clin Pharmacol Ther; 1998 Sep; 64(3):269-77. PubMed ID: 9757150
[TBL] [Abstract][Full Text] [Related]
20. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Takano M
J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
